C4 Therapeutics, Inc. — Director's Dealing 2021

Jul 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-07-02

Reporting Person: COHEN MARC A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-02	Common Stock	A	522	$39.72	Acquired	6641	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1967622	Indirect

Footnotes

F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 2, 2021.

F3: This amount has been adjusted to reflect 92,817 shares previously transferred from the Reporting Person to the Marc Andrew Cohen Revocable Trust.

F4: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust.